Edasalonexent

DRUG3 trials

Sponsors

Catabasis Pharmaceuticals

Conditions

Duchenne Muscular DystrophyMuscular Dystrophy, Duchenne

Phase 1

Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy

CompletedNCT02439216

Catabasis PharmaceuticalsMuscular Dystrophy, Duchenne

Start: 2016-04-30End: 2019-08-31Updated: 2022-09-23

Phase 3

Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

CompletedNCT03703882

Catabasis PharmaceuticalsMuscular Dystrophy, Duchenne

Start: 2018-10-02End: 2020-09-22Updated: 2022-06-21

An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

TerminatedNCT03917719

Catabasis PharmaceuticalsDuchenne Muscular Dystrophy

Start: 2019-03-14End: 2020-10-26Updated: 2020-11-23

Related Papers

Motor Function and Growth Outcomes With Early Corticosteroid Initiation in Duchenne Muscular Dystrophy: An Adjusted Cross‐Trial Comparison

Muscle & Nerve2026-03-20

A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial

Journal of Neuromuscular Diseases2021-06-1128 citations